



G7 Health Minister Meeting
Berlin, Germany
8th October 2015

ANTIMICROBIAL RESISTANCE IN G7 COUNTRIES

Economic Issues, Policies and Options for Action

Stefan Kapferer
Deputy Secretary General




Antimicrobial Resistance is a Global Threat

- Modern medicine and surgery are not possible without antibiotics
- AMR is largely human-driven
 - Inappropriate use in humans
 - Overuse in livestock
 - Insufficient hygiene in hospitals
 - Global trade & travel
- The development pipeline of new antibiotics is drying up




Higher Use of Antibiotics Drives Resistance





AMR Causes a Significant Health Burden



1 in 5 human **infections** in G7 countries **is resistant** to antibiotics

Patients **infected** by resistant bacteria are more likely to incur **health complications**

x3 probability of **local progression** for resistant infections

x2 risk of **any complication** for resistant infections


x3 Risk of **death** for resistant infections



AMR has a Large Cost for Healthcare Systems

Hospitalized patients with antibiotic-resistant infections costs an **additional 10-40k USD**

Over half of extra expenditure is due to nursing and medical care



23b USD additional healthcare spending in Europe and North America per year



AMR has a Negative Economic Impact

Productivity loss

38K USD

per patient due to AMR

labour force


2.1m deaths by 2050

amongst working age population

wider economy impact

affecting mostly

trade & agriculture





Responding to the Rise of Antimicrobial Resistance

Globally:

25% Countries have a national policy to tackle AMR

40% Countries have infection & control programmes for AMR

Good practices



Avoiding the emergence

Stewardship programmes
Immunisation programmes



Avoiding the spread

Early detection
Measures to reduce infectivity
Enhance sanitation and hygiene in medical facilities



Stimulating R&D


De-linking development incentives from sales
Global research platforms



OECD Recommendations to Move Forward in the Fight Against AMR



Coordinating with global partners like the **G20** to efficiently upscale G7 efforts into a **global action**



Strengthening existing **surveillance and monitoring** systems



Adopting globally agreed sets of **measurable targets** on AMR **incidence** and efficient **antibiotic use**



Strengthening ongoing efforts to **rationalise antibiotics** use and **prevention** of **AMR spread**



Fostering **R&D** through a global collaborative **research platform**, and by **delinking development from sales**